Who

we are 

0
LAUNCH
0+
MORE THAN 80 CLIENTS SUPPORTED
0+
YEARS OF CUMULATIVE EXPERIENCE

Alhena Consult was born out of the desire of its associates to work together and to pool their
skills by placing human values at the center.

Alhena is the third brightest star in the Gemini constellation.

Like this star, we want to

Guide you to the success of your projects !

Complementary, dedicated, flexible and caring, we work with your team, providing tailored support throughout the project.

Our culture is to remain focused on your needs and develop mutual trust to build a solid,
long-term partnership.

Rigor – Responsiveness – Trust

Meet the team !

Coming together is the beginning ;

Keeping together is progress ;

Working together is success.

Henry Ford

Peggy CANCE

President and Founder

MORE THAN 20 YEARS OF EXPERIENCE

Her expertise:

  • Regulatory affairs
  • Drug development
  • Early access
  • Scientific writing
  • Project management
  • Team management

Carole SOUCHAIRE

Co-founder

MORE THAN 20 YEARS OF EXPERIENCE

Her expertise:

  • Regulatory affairs
  • Exploitant activities in France
  • Chief Pharmaceutical Officer Deputy
  • Audits
  • Team management

Pascale TRONCHE

Co-founder

MORE THAN 20 YEARS OF EXPERIENCE

Her expertise:

  • Drug development
  • Project leadership/management
  • CMC
  • Team management
  • Regulatory affairs
  • Scientific writing

Aurélia BIDANT

Co-founder

MORE THAN 20 YEARS OF EXPERIENCE

Her expertise:

  • Pharmacovigilance
  • Medical information
  • Early access
  • Scientific writing
  • Team management
  • Audit

Florence BEYTOUT

Senior Consultant Regulatory Affairs

MORE THAN 20 YEARS OF EXPERIENCE

Her expertise:

  • Regulatory affairs
  • Drug development
  • Early access
  • Market access
  • Scientific writing

Sarah ZAHOUANI

R&D Project Manager

MORE THAN 5 YEARS OF EXPERIENCE

Her expertise:

  • Drug development
  • Project management
  • Scientific writing

Mélanie RABY

Consultant Regulatory Affairs

MORE THAN 20 YEARS OF EXPERIENCE

Her expertise:

  • Regulatory affairs
  • Exploitant activities in France
  • Clinical trials
  • Early access